KAPA 8-K: SEC filing
Kairos Pharma
Filed with the SEC on · accession 0001493152-26-050094
KAPA filed a 8-K (current report) with the SEC on Nov 5, 2026. Kairos Pharma announced that its lead candidate ENV-105 (carotuximab) won the 2026 Biotech Breakthrough Awards in the Cancer Immunology Solution of the Year category.
Summary of the filing
Kairos Pharma announced that its lead candidate ENV-105 (carotuximab) won the 2026 Biotech Breakthrough Awards in the Cancer Immunology Solution of the Year category. The press release also referenced recently announced positive interim Phase 2 efficacy data for ENV-105 in combination with apalutamide in metastatic castration-resistant prostate cancer.
Key details
✦ Ask GOAX AI about this filing — what it means for KAPA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for KAPA?
Click hereFrequently asked questions
What did KAPA file with the SEC on Nov 5, 2026?
KAPA filed a 8-K (SEC filing). Kairos Pharma announced that its lead candidate ENV-105 (carotuximab) won the 2026 Biotech Breakthrough Awards in the Cancer Immunology Solution of the Year category. The press release also referenced recently announced positive interim Phase 2 efficacy data for ENV-105 in combination with apalutamide in metastatic castration-resistant prostate cancer.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other KAPA SEC filings
Get alerts when KAPA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days